UK $104 Billion Pharmaceutical Giant GSK Buys United States $9.7 Billion Clinical-Stage Biopharmaceutical Company Nuvalent for $10.6 Billion in All-Cash Deal Representing +40% Premium to Closing Price (9/6/26), Nuvalent Founded in 2017 by Harvard University Chemical Biologist Matthew Shair, Nuvalent Current Market Value at $9.7 Billion, Share Price +22.3% YTD, +55.2% Last 12 Months & +575.8% Last 5 Years
11th June 2026 | Hong Kong
UK pharmaceutical giant GSK ($104 billion market value) has announced to buy United States clinical-stage biopharmaceutical company Nuvalent ($9.7 billion market value) for $10.6 billion in all-cash deal, representing +40% premium to Nuvalent closing price (9/6/26). Nuvalent was founded in 2017 by Harvard University chemical biologist Matthew Shair. Nuvalent current market value at $9.7 billion, share price +22.3% YTD, +55.2% last 12 months & +575.8% last 5 years. Nuvalent – Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. GSK – GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
“ UK $104 Billion Pharmaceutical Giant GSK Buys United States $9.7 Billion Clinical-Stage Biopharmaceutical Company Nuvalent for $10.6 Billion in All-Cash Deal Representing +40% Premium to Closing Price (9/6/26), Nuvalent Founded in 2017 by Harvard University Chemical Biologist Matthew Shair, Nuvalent Current Market Value at $9.7 Billion, Share Price +22.3% YTD, +55.2% Last 12 Months & +575.8% Last 5 Years “
![](https://www.caproasia.com/wp-content/uploads/2025/08/Air-Charter-Service-728x90-1.png")
UK $104 Billion Pharmaceutical Giant GSK Buys United States $9.7 Billion Clinical-Stage Biopharmaceutical Company Nuvalent for $10.6 Billion in All-Cash Deal Representing +40% Premium to Closing Price (9/6/26), Nuvalent Founded in 2017 by Harvard University Chemical Biologist Matthew Shair, Nuvalent Current Market Value at $9.7 Billion, Share Price +22.3% YTD, +55.2% Last 12 Months & +575.8% Last 5 Years
Caproasia Users
- Manage $20 million to $30 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2026 Investment Day
- March - Hong Kong
- March - Singapore
- April - Hong Kong
- April - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
